Presentations day 1

Session: Official opening

• General opening
  Aristotelis Bamias
• 10 years of PROSCA
  Bertrand Tombal
• Official opening PROSCA
  Athanasios Papatsoris – Anna Zygogianni

Session: APCCC 2022 highlights

• APCCC 2022 highlights
  Karim Fizazi – Piet Ost – Bertrand Tombal

Session: Management of intermediate-risk PCa

• Impact of genomic markers
  Eric Klein
• Impact of imaging
  Anwar Padhani
• Case discussion: active surveillance or intervention?
  Julia Murray – Johan Stranne

Session: Follow-up after radical therapy

• Impact of genomic classifiers on treatment
  Alan Dal Pra
• Debate: do we postpone salvage RT until a positive PSMA-PET/CT?
  Presentation Roderick van den Bergh
  Presentation Julia Murray
• Not all that shines is positive
  Karolien Goffin
• PSMA-PET/CT-based RT
  Vérane Achard

Session: Best poster session

• Introduction
  Athanasios Papatsoris
• 1st winner
  Gabriela Ilie
• 2nd winner
  Jean-Paul van Basten
  
• 3rd winner
  Filippos Kapogiannis
  

Session: AR antagonists: are they all equal?

• Presentation
  Bertrand Tombal

Session: High-risk and very high-risk PCa

• Role of surgery in very high-risk PCa
  Steven Joniau
• RT in very high-risk PCa
  Alberto Bossi
• Role of systemic therapy in very high-risk PCa
  Karim Fizazi
• What is the added benefit of new imaging for (very) high-risk patients?
  Anwar Padhani
  

Presentations day 2

Session: Evolving strategies in mHSPC

• Treatment intensification with chemotherapy: does volume matter?
  Silke Gillessen
• Treatment intensification with radiotherapy: does volume matter?
  Nicholas James
• Managing cardiovascular and skeletal comorbidities
  Amit Bahl

Session: Latest techniques and developments in surgery

• Presentation
  Alexandre Mottrie – Ashutosh Tewari

Session: New concepts in PCa pathology

• Presentation
  Eva Compérat

Session: Optimal strategies for patients progressing on AR-pathway inhibitors

• Sequencing treatments in advanced PCa
  Amit Bahl
• PARP inhibitors: single-agent and combinations
  Elena Castro
• Radioligand therapy
  Ken Herrmann
• Case discussion: third-line treatment options
  Amit Bahl – Elena Castro

Session: Oligorecurrent HSPC

• Oligorecurrent PCa: what is it?
  Julia Murray
• Case discussion: how to approach oligorecurrent PCa?
  Vérane Achard – Steven Joniau – Ursula Vogl

Session: Back to the future: 10 years of PROSCA

• Introduction
  Martin Michel
• Surgery: what’s the future?
  Ashutosh Tewari
• Pathology: what’s the future?
  Eva Compérat
• EBRT: what’s the future?
  Alberto Bossi
  
• Medical oncology: what’s the future?
  Eleni Efstathiou
  

Session: Immunotherapy in prostate cancer

• Presentation
  Aurelius Omlin

Session: PROSCA meets BLADDR session

• Cancer patient empowerment programme: Canadian randomised trial and its global implementation
  Gabriela Ilie – Rob Rutlegde
• Do we need more real-world data for PCa and BCa?
  Mieke van Hemelrijck
• ctDNA as a pan-cancer screening test
  Eric Klein